Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome

• Taysha outlined a registration strategy for TSHA-102, a one-time intrathecal AAV9 gene therapy candidate for Rett syndrome.
• REVEAL pivotal trial dosing completed in 17 females ages 6 to <22 years at 1x10^15 total vg; 6-month interim readout targeted for 1H 2027.
• REVEAL Part A data showed a 100% response rate on the primary endpoint in 12 patients; no treatment-related serious adverse events or dose-limiting toxicities reported.
• FDA alignment cited for a potential BLA submission based on the pivotal trial 6-month interim analysis, with Part A data included for comparability.
• ASPIRE trial in 4 females ages 2 to <4 years remained ongoing; dosing completion expected in July 2026 to support a broad label for patients age 2+.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.